Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

Nicolas Jacquelot(University of Calgary), Laurence Zitvogel(Institut Gustave Roussy), Ilaria Marigo(Hammersmith Hospital), Miles C. Andrews(Alfred Health), Romain Daillère(Institut Gustave Roussy), Jean‐Charles Soria(Inserm), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Christophe Klein(Délégation Paris 5), Gabriele Madonna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Armelle Prévost‐Blondel(Délégation Paris 5), Antje Sucker(German Cancer Research Center), Meriem Messaoudene(Centre Hospitalier de l’Université de Montréal), Vincenzo Bronte(University of Verona), Marie Vétizou(Innate Pharma (France)), Shin Foong Ngiow(Parker Institute for Cancer Immunotherapy), Paule Opolon(Institut Gustave Roussy), Connie P.M. Duong(Peter MacCallum Cancer Centre), Mark J. Smyth(Peter MacCallum Cancer Centre), Gautier Stoll(Délégation Paris 5), Aurélien Marabelle(Institut Gustave Roussy), Sonia Becharef(Inserm), Takahiro Yamazaki(Inserm), Guido Kroemer(Institut Universitaire de France), Gladys Ferrere(Institut Gustave Roussy), Loïc Verlingue(Université Paris-Sud), Vancheswaran Gopalakrishnan(AstraZeneca (United States)), David Enot(Institut Gustave Roussy), Alexander Eggermont(University Medical Center Utrecht), Pierre-Olivier Gaudreau(Queen's University), María P. Roberti(Inserm), Stefano Ugel(University of Verona)
Cell Research
September 3, 2019
Cited by 246


Related Papers